Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:APHBNYSEAMERICAN:BPMXNYSE:CYBNOTCMKTS:NGENF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHBAmpliphi Biosciences$2.03-0.5%$1.46$0.15▼$1.37$67.94MN/A842,200 shs30,566 shsBPMXBiopharmx$0.00$0.25▼$6.30$111.86MN/A2.15 million shs336,508 shsCYBNCybin$8.65-0.7%$7.18$4.81▼$13.88$198.17M0.68262,707 shs190,074 shsNGENFNervGen Pharma$2.93+2.9%$2.67$1.46▼$5.10$181.20MN/A149,263 shs278,211 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHBAmpliphi Biosciences+3.57%+4.64%+57.36%+8.56%-25.37%BPMXBiopharmx0.00%0.00%0.00%0.00%0.00%CYBNCybin-0.69%-1.93%+31.26%+14.27%+2,244.17%NGENFNervGen Pharma+2.93%+32.16%+14.14%+54.39%+65.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin3.0185 of 5 stars3.60.00.00.03.90.81.3NGENFNervGen PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHBAmpliphi Biosciences 0.00N/AN/AN/ABPMXBiopharmx 0.00N/AN/AN/ACYBNCybin 3.25Buy$86.00894.22% UpsideNGENFNervGen Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APHB, CYBN, NGENF, and BPMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/ANGENFNervGen Pharma$150K1,207.97N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/ABPMXBiopharmxN/AN/A0.00N/AN/AN/AN/AN/AN/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ANGENFNervGen Pharma-$4.07MN/AN/A∞N/AN/A-73.14%-56.59%8/20/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/ABPMXBiopharmxN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/ANGENFNervGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHBAmpliphi BiosciencesN/AN/AN/ABPMXBiopharmxN/AN/AN/ACYBNCybinN/A24.2424.24NGENFNervGen Pharma0.0411.2111.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHBAmpliphi BiosciencesN/ABPMXBiopharmxN/ACYBNCybin17.94%NGENFNervGen PharmaN/AInsider OwnershipCompanyInsider OwnershipAPHBAmpliphi BiosciencesN/ABPMXBiopharmxN/ACYBNCybin15.00%NGENFNervGen PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableBPMXBiopharmx1718.28 millionN/ANot OptionableCYBNCybin5022.91 million17.96 millionNot OptionableNGENFNervGen Pharma761.77 millionN/ANot OptionableAPHB, CYBN, NGENF, and BPMX HeadlinesRecent News About These CompaniesNervGen Pharma-Aktie stürzt nach Ergebnissen klinischer Studie abJune 2, 2025 | de.investing.comNervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord InjuryJune 2, 2025 | taiwannews.com.twNervGen Pharma stock tumbles following clinical trial resultsJune 2, 2025 | in.investing.comNervGen, Sprott Climb to 52-Week Highs on NewsMay 21, 2025 | baystreet.caNervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific MeetingMay 21, 2025 | newsfilecorp.comNervGen Pharma Grants Stock OptionsMay 16, 2025 | newsfilecorp.comNervGen Pharma Reports Q1 2025 Financial Results and Provides Operational UpdatesMay 15, 2025 | newsfilecorp.comNervGen Pharma Announces Results of Annual General Meeting of ShareholdersMay 7, 2025 | newsfilecorp.comNervGen Pharma is a high-risk, high-reward stock, analyst saysApril 21, 2025 | cantechletter.comNervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 21, 2025 | newsfilecorp.comNervGen Pharma Updates on Equity Program, Raises Over $1.6 MillionApril 9, 2025 | tipranks.comNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNervGen Provides Quarterly "At-The-Market" Equity Program UpdateApril 9, 2025 | newsfilecorp.comNervGen Pharma Reports 2024 Year-End Financial Results and Provides Business UpdatesApril 3, 2025 | newsfilecorp.comNervGen Initiates Expanded Access PolicyMarch 31, 2025 | newsfilecorp.comNervGen Pharma to Host Virtual Investor EventMarch 25, 2025 | globenewswire.comNervGen Pharma Grants Stock OptionsMarch 14, 2025 | newsfilecorp.comNervGen Pharma to Present at the Virtual Life Science Investor ForumMarch 5, 2025 | newsfilecorp.comNervGen Pharma Grants Stock OptionsFebruary 18, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPHB, CYBN, NGENF, and BPMX Company DescriptionsAmpliphi Biosciences NYSEAMERICAN:APHB$2.03 -0.01 (-0.49%) As of 06/11/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Biopharmx NYSEAMERICAN:BPMXBioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.Cybin NYSE:CYBN$8.65 -0.06 (-0.69%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$8.54 -0.11 (-1.27%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.NervGen Pharma OTCMKTS:NGENF$2.93 +0.08 (+2.93%) As of 06/12/2025 03:55 PM EasternNervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
